Compounders Research Compare

Quince Therapeutics, Inc.(QNCX)

Biotechnology · South San Francisco, CA

$27.15-0.95 (-3.38%)

Delayed quote: Oct 6, 2026, 3:39 PM EDT

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

South San Francisco, CA

38 employees

www.quincetx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Dirk Thye

View full financials

Free Cash Flow Yield: N/A

Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The free cash flow yield is N/A as of 2026-10-06T19:43:03.412Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:43:03.412Z.

Quote observation: 2026-10-06T19:39:53.000Z. Amounts in USD. The price header may show a later quote.

TTM free cash flow · period ending 2026-06-30: -47,001,000
Quote market capitalization: 7,558,582

FMP input reference: 2fc0b38e6dc372860fd9bea61ccff40ee6de978c8f50a2bbdf53c6942eb71849

Free Cash Flow CAGR|Earnings Yield|Dividend Yield|P/FCF Ratio|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

QNCX Free Cash Flow Yield Metrics

FREE CASH FLOW YIELD

N/A

QNCX Competitors' Free Cash Flow Yield

Quince Therapeutics, Inc.

Current

Market Cap

$7.56M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mangoceuticals, Inc.

Market Cap

$7.30M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENDRA Life Sciences Inc.

Market Cap

$7.65M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNS Pharmaceuticals, Inc.

Market Cap

$7.76M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InMed Pharmaceuticals Inc.

Market Cap

$7.36M

Free Cash Flow Yield

N/A

TTM Avg

0.00%

3Y Avg

0.00%

5Y Avg

0.00%

Skye Bioscience, Inc.

Market Cap

$7.29M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aprea Therapeutics, Inc.

Market Cap

$7.92M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Traws Pharma, Inc.

Market Cap

$7.90M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Longeveron Inc.

Market Cap

$7.18M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HeartSciences Inc.

Market Cap

$8.04M

Free Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	FREE CASH FLOW YIELD	TTM	3Y	5Y
Quince Therapeutics, Inc. (QNCX)	$7.56M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$7.30M	N/A	N/A	N/A	N/A
ENDRA Life Sciences Inc. (NDRA)vs ›	$7.65M	N/A	N/A	N/A	N/A
CNS Pharmaceuticals, Inc. (CNSP)vs ›	$7.76M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.36M	N/A	0.00%	0.00%	0.00%
Skye Bioscience, Inc. (SKYE)vs ›	$7.29M	N/A	N/A	N/A	N/A
Aprea Therapeutics, Inc. (APRE)vs ›	$7.92M	N/A	N/A	N/A	N/A
Traws Pharma, Inc. (TRAW)vs ›	$7.90M	N/A	N/A	N/A	N/A
Longeveron Inc. (LGVN)vs ›	$7.18M	N/A	N/A	N/A	N/A
HeartSciences Inc. (HSCS)vs ›	$8.04M	N/A	N/A	N/A	N/A

Yield Comparison

FCF Yield

N/A

Earnings Yield

N/A

Dividend Yield

N/A

Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100

How FCF Yield is used:

Shows free cash flow after capital expenditures relative to market cap
Can be compared with earnings yield and dividend yield
Can be compared with the company's historical range
Can be compared with peers that report positive free cash flow

FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.

Free Cash Flow Yield Formula & Definition

FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow CAGR Earnings Yield Dividend Yield P/FCF Ratio All Metrics